Longitudinal Fecal Shedding of SARS-CoV-2, Pepper Mild Mottle Virus, and 1 Human Mitochondrial DNA in COVID-19 Patients 2

3 Pengbo Liu^{1*}, Orlando III Sablon¹, Yuke Wang¹, Stephen Patrick Hilton¹, Lana Khalil², Jessica Mae Ingersoll³, Jennifer Truell³, Sri Edupuganti², Ghina Alaaeddine², Amal Naji², Eduardo 4 5

- Monarrez², Marlene Wolfe¹, Nadine Rouphael², Colleen Kraft³, Christine L. Moe^{1*}
- 6 ¹Center for Global Safe Water, Sanitation, and Hygiene, Rollins School of Public Health, Emory 7 University, Atlanta, Georgia, USA
- 8 ²Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine,
- 9 School of Medicine, Emory University, Atlanta, Georgia, USA
- 10 ³Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
- 11 *These authors share senior authorship
- 12

13 ABSTRACT

- Since the coronavirus disease 2019 (COVID-19) pandemic, wastewater-based 14
- 15 epidemiology (WBE) has been widely applied in many countries and regions for
- 16 monitoring COVID-19 transmission in the population through testing severe acute
- 17 respiratory syndrome coronavirus 2 (SARS-CoV-2) in wastewater. However, the lack of
- 18 dynamic level of viral shedding in the wastewater and accurate number of infections in
- 19 the community creates challenges in predicting COVID-19 prevalence in the population
- and interpreting WBE results. In this study, we measured SARS-CoV-2, pepper mild 20
- 21 mottle virus (PMMoV), and human mitochondrial DNA (mtDNA) in longitudinal fecal
- 22 samples collected from 42 COVID-19 patients for up to 42 days after diagnosis. SARS-
- 23 CoV-2 RNA was detected in 73.1% (19/26) of inpatient study participants in at least one
- of the collected fecal specimens during the sampling period. Most participants shed the 24
- 25 virus within three weeks after diagnosis, but five inpatient participants still shed the virus
- 26 between 20 and 60 days after diagnosis. The median concentration of SARS-CoV-2 in
- 27 positive fecal samples was 1.08x10⁵ genome copies (GC)/gram dry fecal material.
- 28 PMMoV and mtDNA were detected in 99.4% (154/155) and 100% (155/155) of all fecal

29	samples, respectively. The median concentrations of PMMoV RNA and mtDNA in fecal		
30	samples were 1.73x10 ⁷ and 2.49x10 ⁸ GC/dry gram, respectively. These results provide		
31	important information about the dynamics of fecal shedding of SARS-CoV-2 and two		
32	human fecal indicators in COVID-19 patients. mtDNA showed higher positive rates,		
33	higher concentrations, and less variability between and within individuals than PMMoV		
34	suggesting that mtDNA could be a better normalization factor for WBE results than		
35	PMMoV.		
36	Key Words: SARS-CoV-2; COVID-19; longitudinal; fecal shedding; PMMoV; mtDNA		
37			
38	1. INTRODUCTION		

COVID-19 (coronavirus disease 2019) is caused by SARS-CoV-2 (severe acute 39 40 respiratory coronavirus 2), a positive-sense single-stranded RNA virus. Although COVID-19 is a respiratory disease and patients predominantly manifest respiratory 41 42 symptoms, systemic and respiratory manifestations are often accompanied by 43 gastrointestinal symptoms and fecal shedding of viral RNA. Meta-analysis of studies that focus on gastrointestinal (GI) infection and fecal shedding in patients with COVID-44 45 19 report the prevalence of GI symptoms to be around 17.6% (1) and 28.5% (2) in 46 patients with severe COVID-19 during the acute infection phase. In COVID-19 patients, 47 the prevalence of positive RNA in stool samples was about 50% (1, 3) within the first 48 week of diagnosis. Interestingly, several studies that have collected paired longitudinal respiratory and fecal samples demonstrated prolonged fecal shedding and higher viral 49 50 load in feces compared to the paired respiratory samples collected at the same time 51 period (3, 4). This suggests that SARS-CoV-2 infection of the GI tract persists longer

52 than in the respiratory tract and the GI tract excretes more viruses than the respiratory tract. SARS-CoV-2 concentration in stool was reported to be between 10² to 10⁷ GC/mL 53 54 in an early study (5) for the prototype SARS-CoV-2, but there is a lack of this information for the recent variants. 55 56 While the presence and prevalence of SARS-CoV-2 RNA in the GI tract are well 57 established, much less is known about the duration and the amount of SARS-CoV-2 fecal shedding in patients with COVID-19. Natarajan et al. (3) reported that 12.7% of 58 59 subjects still shed SARS-CoV-2 at 4 months and 3.8% of patients shed SARS-CoV-2 at 60 7 months post diagnosis. Whereas there was no evidence of ongoing oropharyngeal 61 virus shedding at this time. Additionally, one study suggested that fecal SARS-CoV-2 62 RNA shedding may start 3-4 days before the onset of the symptoms (5), indicating that 63 the duration of SARS-CoV-2 fecal shedding may be even longer. 64 Many studies have observed significant correlations between the SARS-CoV-2 RNA 65 concentration in wastewater and the number of confirmed COVID-19 cases reported in 66 the corresponding wastewater catchment areas (6-12), which highlights the application of WBE to monitor the burden of viral infection in the population. Other studies have 67 68 attempted to use SARS-CoV-2 fecal shedding levels as parameters in models to predict 69 the prevalence or incidence of COVID-19 in communities (8, 13, 14). Predicting 70 prevalence or incidence in the population is critical for public health decision-making. This application has been explored via several statistical modeling approaches (14-16); 71 However, using modeling to accurately predict COVID-19 prevalence or incidence in 72 73 populations from SARS-CoV-2 concentrations in wastewater requires longitudinal and 74 quantitative SARS-CoV-2 fecal shedding data. To date, there have been several reports on SARS-CoV-2 fecal shedding, but many studies lack longitudinal samples,

quantitative SARS-CoV-2 concentrations (report Ct values rather than absolute
quantification) in stool, accurate timing of when the samples were collected after the
onset of symptoms, specific amount of fecal material used for viral quantification, and
the limit of detection of the assay used for viral quantification, etc. This missing
information in fecal shedding data limits the appropriate application of the models and
the interpretation of WBE modeling results.

82 Pepper mild mottle virus (PMMoV) and human mitochondrial DNA (mtDNA) are two

83 human fecal indicators which are often analyzed along with SARS-CoV-2 quantification

in wastewater samples, and both are used for normalization of SARS-CoV-2

85 concentrations in wastewater. PMMoV, a plant RNA virus that causes infection in

86 pepper crops, is excreted in high concentrations in human fecal material if people

87 consume food products containing infected peppers. Up to 10⁹ virion particles of

88 PMMoV have been reported per gram of human feces by dry weight (17). Because of its

89 abundance in human stool, persistence in the environment, and multiple exposure

90 pathways to humans, PMMoV is frequently reported as a human fecal indicator in WBE

studies (18, 19). Human mtDNA is exclusively human in origin and highly abundant in

92 human feces. However, it is less frequently reported (20, 21) than PMMoV and is

93 potentially a new, reliable human fecal indicator. This marker has been detected in high

copy numbers in 100% of human fecal specimens across multiple geographic regions

95 (22) and in 92% of sewage samples (23).

The objective of this study was to examine the fecal shedding dynamics of SARS-CoV-2
 RNA, PMMoV, and mtDNA in longitudinal fecal samples collected from confirmed

- 98 COVID-19 inpatient and outpatient participants. The results can be used to better
- 99 predict COVID-19 prevalence or incidence in communities using mathematical modeling
- and guide interpretation of SARS-CoV-2 RNA levels in wastewater samples using WBE
- 101 approaches.
- 102

103 2. MATERIALS and METHODS

104 **2.1. Study Description and Stool Sample Collection**

105 Study participants were recruited from the inpatient clinic at Emory University Hospital 106 between March 21, 2021 and September 21, 2021 and the outpatient clinic by the Hope 107 Clinic of Emory Vaccine Center between September 22, 2021 and July 28 2022. All 108 participants were required to sign an informed consent. In addition, information on 109 demographics, clinical symptoms, and COVID-19 vaccination was also collected. 110 COVID-19 patients were enrolled as study participants if an in-house real-time RT-PCR 111 test detected SARS-CoV-2 RNA in their nasopharyngeal swab samples or other 112 commercial assays (e.g., antigen test) showed SARS-CoV-2 antigen in their saliva 113 specimens within 7 days after the onset of COVID-19 symptoms. Participants with any 114 behavioral, cognitive, or psychiatric condition were excluded from the enrollment. The 115 day with SARS-CoV-2 positive detection was considered the COVID-19 confirmation 116 date in this study. The first stool sample was collected after the participant was enrolled, 117 usually within 7 days after the confirmation date. The date of the first stool sample 118 collection was defined as Day 1, and subsequent samples were collected on Days 3, 7, 119 14, 28, and 42 from the first stool sample for each subject. The sampling day was 120 converted to the day of COVID-19 confirmation for data analysis and visualization

purposes. Stool collection kits were provided to study participants. For inpatients, stool samples were picked up from the hospital room and there was usually no delay. For outpatients, stool collection kits were shipped to the home address, and study participants were asked to ship samples back to the Emory study lab using prepaid mailers. These samples were usually delayed for shipment and may not have been kept all the way in the cold chain. Once received by the study lab, the samples were immediately stored at -80°C prior to nucleic acid extraction and RT-qPCR detection.

128 **2.2. Fecal Sample Processing and Nucleic Acid Extraction**.

129 Stool samples were processed by the physical disruption method of bead lysing 130 followed by total nucleic acid extraction with an automated purification platform, Qiagen 131 EZ1 Advanced XL (Qiagen, #9001875). First, fecal specimens were thawed on ice from 132 -80°C. Each specimen was precisely weighed on an analytical balance, ranging between 27.0 mg to 33.1 mg, into a 2.0 mL pre-filled 0.7 mm garnet bead tube (Omni 133 134 International, #19-624). Then, 600 µL of Qiagen PowerBead solution (Qiagen, #12955-135 4-BS) was added to each wet sample. Specimens were immediately mixed on a Bead 136 Genie (Scientific Industries Inc, #SI-B100) at 3,000 rpm for 2 minutes, which introduces 137 physical agitation resulting in the lysing of the sample matrix and homogenizing the 138 sample. A 200 μ L aliquot of lysate was added to 5,000 genome copies (10 μ L) of 139 Bovine Respiratory Syncytial Virus (BRSV) (INFORCE 3, Zoetis, Parsippany, NJ) and 140 processed by the Qiagen EZ1 Advanced XL with the Qiagen EZ1 DSP virus kit (Qiagen, 141 # 62724) and Qiagen EZ1 Advanced DSP Virus Card (Qiagen, #9018306). BRSV 142 served as an internal processing control during the concentration and extraction 143 procedures. Total nucleic acids were extracted by a Zymo Research OneStep™ PCR

144	Inhibitor Removal kit (Zymo Research, #D6030). A Zymo-Spin™ III-HRC Column
145	(Zyme Research, #C1005) was used for each sample as per the manufacturer's
146	instructions. We inserted the column into a collection tube and added 600 μL of Prep-
147	Solution. Then, we centrifuged the column at $8,000 \times g$ for 3 minutes. The prepared
148	column was transferred to a clean 1.5 ml microcentrifuge tube, and 60 μL of RNA was
149	added to the Zymo-Spin [™] III-HRC Column. The sample was then centrifuged at 16,000
150	× g for 3 minutes. Total nucleic acid was collected and stored at 80° C.To estimate the
151	dry weight, each fecal sample was weighed, placed onto an aluminum weigh boat,
152	incubated at 105-110°C for 24 hours, and re-weighed after incubation.
153	The dry weight percent for the calculation of SARS-CoV-2 concentrations per mass of
154	dry weight was calculated using the following formula:
155	[1-(wet mass of fecal material - dry mass of fecal material)/wet mass of fecal material]
156	×100%
157	2.3. Quantification of SARS-CoV-2, PMMoV, and mtDNA in Stool Samples using
158	dPCR
159	Digital PCR was performed using the QIAcuity Digital PCR System and QIAcuity
160	OneStep Advanced Probe Kit (Qiagen, #250132) following the manufacturer's protocol.
161	The Qiagen QIAcuity instrument was programmed using the following parameters.
162	Reverse transcription was set at 50°C for 40 minutes for 1 cycle followed by PCR initial
163	heat activation at 95°C for 2 minutes. The PCR was repeated for 45 cycles at 95°C for 5
164	seconds, and at 50°C for 30 seconds. One triplex PCR was used to quantify PMMoV,

165 BRSV, and N1 (nucleocapsid gene) of SARS-CoV-2, while mtDNA was quantified in a

166	singleplex assay. For the triplex PCR assay, each 40- μ L reaction contained 10 μ L of 4×
167	One-step Advanced Probe Master Mix, 0.4 μL of 100× OneStep RT Mix, 2 μL of each
168	16× primer-probe mix of PMMoV, BRSV, and N1, 5 μ L of nucleic acid extract, and 18.6
169	μL of RNase-free water. For the mtDNA singleplex master mix, each 40- μL reaction
170	contained 10 μL of 4× One-step Advanced Probe Master Mix, 0.4 μL of 100× OneStep
171	RT Mix, 2 μ L of 16× primer-probe mix of mtDNA, 5 μ L of 1:100 diluted nucleic acid
172	extract, and 22.6 μL of RNase-free water. The master mix was pipetted into a QIAGEN
173	QIAcuity 24 well 26k partition nanoplate.

174 **2.4. Data Analysis and Statistics**

We performed data analysis using R program (version 4.0.1). A logistic regression
model was used to study the association between SARS-CoV-2 positivity and other
variables including inpatient, outpatient, days after COVID-19 was confirmed, PMMoV,
and mtDNA concentration. The Pearson correlation was used to estimate the

association between log₁₀-transformed PMMoV and mtDNA concentrations.

180 3. RESULTS

181

182 **3.1. Participant Description**

A total of 42 subjects with confirmed COVID-19 were enrolled in this study, and 155 fecal samples were collected throughout the 42-day follow-up period. Most of these subjects, 61.9% (26/42), were inpatients, and 38.1% (16/42) were outpatients. Most participants manifested severe clinical symptoms if hospitalized (inpatients), while outpatient participants usually had mild symptoms. The self-reported COVID-19 vaccination status indicated that 66.7% (28/42) were vaccinated (received at least one

189	dose of COVID-19 vaccine and had a breakthrough infection) and 33.3% (14/42) were
190	unvaccinated. Among these subjects, only 14.3% (6/42) were ≥65 years old (Table 1).
191	3.2. COVID-19 Clinical Symptoms
192	To compare the clinical course of infections of vaccinated and unvaccinated
193	participants, clinical symptoms relevant to COVID-19 infection were assessed. Cough,
194	diarrhea, fever, loss of smell, and shortness of breath were more frequently observed in
195	unvaccinated subjects than in vaccinated subjects. Frequencies of headache and
196	myalgia fatigue were higher in vaccinated and in unvaccinated groups. When inpatients
197	and outpatients were compared, inpatients were much more likely to report cough,
198	diarrhea, and fever than outpatients while outpatients tended to have more symptoms of
199	headache, loss of smell, myalgia and fatigue. These differences may be caused by the
200	small number of subjects in both groups (Table 2).
201	3.3. Longitudinal SARS-CoV-2 Fecal Shedding
202	The SARS-CoV-2 fecal shedding patterns for each inpatient and outpatient study
203	subject are shown in Figure 1. SARS-CoV-2 RNA was detected in at least one of the
204	fecal samples collected during the sampling period for 73.1% (19/26) of inpatient
205	participants. Most SARS-CoV-2 RNA-positive samples were collected within two weeks
206	of COVID-19 diagnosis. Five inpatients still shed the virus in their stools after two

207 weeks, and one inpatient had detectable SARS-CoV-2 RNA in a stool sample at 59

208 days after COVID-19 diagnosis. For the 71 fecal samples collected from inpatients,

47.9% (34/71) had SARS-CoV-2 N1 gene measurements above the limit of detection of

our PCR assay. In contrast, outpatients showed a different fecal shedding pattern. Only

211 7.1% of 84 fecal samples collected from 16 outpatients were SARS-CoV-2 RNA

212 positive, and all of these came from four study subjects. The low proportion of SARS-

- 213 CoV-2 positive stool samples from outpatients may be due to delays in sample
- collection. Interestingly, all four outpatient subjects with positive SARS-CoV-2 stool
- samples were intermittent shedders and were excreting the virus at three or more
- 216 weeks after infection was confirmed.

217 3.4. SARS-CoV-2 RNA Concentrations in Fecal Specimens

- 218 Concentrations of SARS-CoV-2 RNA in stool samples ranged from 4.5x10³ genome
- copies (GC)/dry gram to 1.19×10^9 GC/dry gram with a median of 1.08×10^5 GC/dry gram.
- 220 For the 34 fecal samples from inpatients that tested positive for SARS-CoV-2 RNA, the
- median concentration of SARS-CoV-2 RNA was 1.35x10⁵ GC/dry gram. For the six
- fecal samples from outpatient participants that tested positive for SARS-CoV-2 RNA,
- the median concentration of SARS-CoV-2 RNA was 9.11x10³ GC/dry gram (Figure 2,
- bottom left). Both the SARS-CoV-2 detection rates in stool samples and the mean virus
- RNA log₁₀ concentrations in stool were significantly different in samples from inpatients
- versus outpatients (p<0.001 and p=0.003, respectively).

3.5. Fecal Shedding Among Vaccinated (Breakthrough) and Unvaccinated Participants

- 229 There was little difference in the detection rates and concentrations of SARS-CoV-2
- 230 RNA in fecal samples from study subjects with different COVID-19 vaccination status.
- For the 28 vaccinated participants, 53.6% (15/28) of vaccinated participants shed
- 232 SARS-CoV-2 in at least one of the fecal specimens collected during the study period,
- and 26.2% (28/107) fecal samples from vaccinated participants were SARS-CoV-2 RNA
- positive with a median concentration of 1.08x10⁵ GC/dry gram. There were 14
- participants who reported that they were unvaccinated, and 8 of them (57.1%) had
- evidence of SARS-CoV-2 shedding in at least one of the collected fecal samples. Of the

- 48 fecal samples collected from unvaccinated participants, 25.0% (12/48) fecal samples
- from unvaccinated participants were positive for SARS-CoV-2 RNA and the median
- concentration was 9.14 x10⁴ GC/dry gram (Figure 2, bottom right).
- 240 **3.6. PMMoV Detection in Fecal Samples**
- 241 PMMoV was analyzed in each fecal sample by dPCR on the same day as the SARS-
- 242 CoV-2 dPCR to observe the biological variability of this fecal indicator within and
- between individuals over the sampling period. Almost all (99.4%, 154/155) of the fecal
- samples in this study had detectable PMMoV. The median concentration of PMMoV
- 245 RNA was 1.73x10⁷ GC/dry gram. PMMoV RNA concentrations were highly variable over
- the sampling period within and between the individual study subjects. Some individuals
- showed relatively consistent concentrations of PMMoV RNA in their longitudinal
- samples; while for others the PMMoV RNA concentrations varied across several orders
- of magnitude among all the samples from an individual. The lowest PMMoV
- concentration was 790 GC/dry gram, and the highest concentration was 3.51x10⁹
- 251 GC/dry gram (Figure 3).

252 **3.7. Human mtDNA Detection in Fecal Samples**

- Human mtDNA, another fecal indicator, was analyzed in all the collected fecal samples.
- All 155 samples (100%) tested positive for mtDNA, and the median concentration of
- 255 mtDNA in all positive samples was 2.49x10⁸ GC/dry gram. The concentration of mtDNA
- ranged between 8.22x10⁶ GC/dry gram and 3.88x10¹⁰ GC/dry gram. In contrast to
- 257 PMMoV, the mtDNA concentration in stool was more consistent both between and
- within the study subjects over the study period (Figure 4).
- 259 3.8. Correlation between PMMoV and mtDNA

Pearson correlation analysis was performed to examine the association between PMMoV and mtDNA concentrations, the two human fecal markers measured in the fecal samples in this study. Figure 5 indicated a weak correlation (p = 0.16) between the concentrations of these two markers. Interestingly, mean log₁₀ PMMoV concentration was significantly higher (p < 0.001) in fecal specimens from outpatients compared to those from inpatients.

266

267 **4. DISCUSSION**

268 In this study, we describe frequency, duration, and concentration of SARS-CoV-2, 269 PMMoV, and mtDNA shedding in fecal specimens from inpatient and outpatient study 270 subjects with COVID-19 over a 42 day period after the confirmation of SARS-CoV-2 271 infection. Consistent with other reports (24-26), study subjects who had been 272 vaccinated but had breakthrough infections were less likely to exhibit some clinical 273 symptoms, such as cough, diarrhea, fever, loss of smell, loss of taste, and shortness of 274 breath, compared to unvaccinated study subjects. Inpatient participants were more likely to be shedding SARS-CoV-2 RNA in their fecal specimens and had higher 275 276 concentrations of the virus in their stool compared to outpatient participants. These results provide important information about the dynamics of the fecal shedding of 277 278 SARS-CoV-2 and two human fecal indicators. Understanding the presence, magnitude, 279 and duration of these targets of interest is critical for the broad application of WBE and 280 interpretation of WBE results.

Although several cross-sectional studies have reported SARS-CoV-2 fecal shedding in patients with COVID-19 at the early stage of infection, little is known about longitudinal SARS-CoV-2 shedding. In this study, we observed that 73.1% (19/26) inpatients shed

284 SARS-CoV-2 up to three weeks and 19.2% (5/26) inpatients continued to shed viruses beyond day 20; however only 25.0% (4/16) outpatients shed viruses after three weeks 285 286 of diagnosis. In contrast, the study led by Natarajan et al., (3) included a total of 113 287 individuals diagnosed with COVID-19 who were followed for up to 10 months. They 288 reported that 49.2% of fecal specimens tested positive for SARS-CoV-2 during the week 289 following diagnosis using PCR-based methods, with the positivity rate declining to 290 12.7% at 4 months and 3.8% at 7 months after diagnosis. Another study reported the 291 fecal shedding results from 48 SARS-CoV-2 infected individuals and observed that 292 approximately 80% of the fecal samples collected within the first 5 days were positive 293 for SARS-CoV-2, and this positivity rate dropped to 10% at 28 days after symptom 294 onset. A median concentration of three orders GC of magnitude/mg dry weight was 295 reported in positive fecal samples (27), which is one order GC of magnitude higher 296 compared to this study.

297 Normalizing SARS-CoV-2 concentrations measured in wastewater with a human fecal 298 indicator is a common practice in order to adjust for factors that may contribute to the variability in SARS-CoV-2 concentrations from distinct catchment areas and the 299 300 recovery of the virus from wastewater with different methods. Several fecal indicators, 301 including human ribonuclease P (37), PMMoV (38), Bacteroides HF183 (39); F-specific 302 RNA bacteriophages (40), human 18S rRNA (41), cross-assembly phage (CrAssphage) 303 (42), have been proposed. Among these recommended fecal indicators, PMMoV is 304 widely used. PMMoV is a plant RNA virus associated with pepper products and human 305 diet (17, 38). The presence and magnitude of PMMoV RNA in biological and 306 environmental samples are varied due to the geographic and dietary variations between

307 populations and individuals. These variations may complicate the application of PMMoV 308 as a normalizing indicator in some situations, such as countries with less consumption 309 of plants and pepper products. Although PMMoV has been consistently detected in 310 wastewater and has been proposed as a normalization indicator, there are few reports 311 characterizing PMMoV detection in human fecal samples. Additionally, high 312 concentrations of PMMoV have been detected in non-human fecal samples, such as 313 chickens and seagulls (43, 44), indicating that PMMoV is not human-specific and 314 detection of PMMoV in wastewater may originate from other non-human sources, eg., 315 livestock and wildlife. Therefore, accurate characterization of the frequency of detection 316 and quantification of PMMoV in human fecal samples provides critical information for 317 better application of this marker as a normalization control in WBE. In this study, 318 PMMoV was detected in 99.4% fecal samples, with a median concentration of 1.73×10^7 319 GC/dry gram. The PMMoV concentrations measured in this study are similar to those 320 reported in one recent publication that also quantified PMMoV in human stool samples 321 using digital PCR and reported dry mass concentrations (27). In concordance with their 322 results, we observed significant variations of PMMoV concentrations between and 323 within individuals throughout the sampling period. This suggests that PMMoV levels in 324 human fecal materials may be affected by an individual's daily diet and lifestyle.

Human mtDNA is a human-specific intrinsic genetic marker for fecal source tracking. This marker is abundant in human feces and sewage which makes it a useful indicator of human fecal contamination for environmental microbial research and risk assessment applications (22, 23, 45, 46). There are limited reports on the use of mtDNA as a normalization control in SARS-CoV-2 wastewater studies. In this study, mtDNA was

330 detected in 100% fecal samples, with a median concentration of 2.49×10⁸ GC/dry gram. 331 Our mtDNA concentrations are within the range of mtDNA concentrations in human 332 feces reported by other studies(45). Compared to PMMoV detection in human feces, 333 mtDNA was detected in all the fecal specimens, was present at ten-fold higher 334 concentrations, and exhibited little variability between and within individuals. 335 Furthermore, there are no non-human sources of this marker. These characteristics 336 suggest that mtDNA may be better suited for use as a normalization factor for WBE 337 results than PMMoV.

338 There are several limitations in this study. First, the sample size was small, with 42 339 confirmed COVID-19 patients enrolled and 155 fecal samples collected. This population 340 was not large enough to allow for stratification for further examination of the effects of 341 some demographic variables on the fecal shedding of SARS-CoV-2. Second, the 342 recruited subjects were from a limited geographic area, basically within the metro 343 Atlanta area of Georgia. Therefore, the sample may not be representative of the US 344 population, and the conclusions may not be generalizable. Third, the fecal samples 345 were collected between March 21, 2021 and July 28, 2022, when the Delta and 346 Omicron variants were prevalent. We do not know the shedding dynamics of other 347 SARS-CoV-2 variants, and the small sample size did not allow us to compare the 348 shedding dynamics of the Delta versus Omicron variants. Fourth, outpatient participants 349 had much lower proportion of SARS-CoV-2 positive fecal specimens than inpatient 350 participants in this study, and surprisingly, all the fecal samples from outpatient study 351 subjects were negative for SARS-CoV-2 within the first three weeks of COVID-19 352 diagnosis. The low SARS-CoV-2 detection rate in fecal specimens from outpatient

participants may be due to the delays between subject enrollment and stool sample
collection and possible mishandling during storage and shipment from the participants'
homes to the research laboratory. In contrast, fecal specimens from inpatient
participants were collected earlier in the course of infection and stored under optimum
conditions until analysis. Despite these limitations, the quantitative measurements of
SARS-CoV-2, PMMoV, and mtDNA in longitudinal fecal samples from confirmed
COVID-19 patients have significant relevance to our understanding of COVID-19
epidemiology, and the SARS-CoV-2 shedding information addresses a critical
knowledge gap for the advancement of WBE and the use of wastewater monitoring data
for SARS-CoV-2 to estimate COVID-19 prevalence and incidence in specific catchment
populations.
5. ACKNOWLEDGEMENTS
This study was supported by the NIH Rapid Acceleration of Diagnostics (RADx)
initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a
initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a contract from Ceres Nanosciences to Emory University. We are grateful to Salvins J.
initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a contract from Ceres Nanosciences to Emory University. We are grateful to Salvins J. Strods, Shawn Mulvaney, Chipo Chemoyo J. Baker Afamefuna, and Jenica Patterson
initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a contract from Ceres Nanosciences to Emory University. We are grateful to Salvins J. Strods, Shawn Mulvaney, Chipo Chemoyo J. Baker Afamefuna, and Jenica Patterson with the NIH RADx Initiative, and Ross Dunlap, Robbie Barbero, and Ben Lepene from
initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a contract from Ceres Nanosciences to Emory University. We are grateful to Salvins J. Strods, Shawn Mulvaney, Chipo Chemoyo J. Baker Afamefuna, and Jenica Patterson with the NIH RADx Initiative, and Ross Dunlap, Robbie Barbero, and Ben Lepene from Ceres Nanosciences, Inc.

381

382

383 Table 1. Demographic Characteristics of 42

384 Study Participants

	Yes (%)
Male	17 (40.5)
Inpatient	26 (61.9)
Vaccinated	28 (66.7)
White	24 (57.1)
Hispanic or Latin	1 (2.4)
Age (≥65 years old)	6 (14.3)

³⁸⁵

386

387

388

Table 2. Symptoms Among Patients Participants

	Vaccination Status		Admission Status	
Symptom	Vaccinated (N=28) %	Unvaccinated (N=14) %	Inpatient (N=26) %	Outpatient (N=16) %
Cough	35.7	71.4	61.9	18.8
Diarrhea	7.1	28.6	14.3	6.2
Fever	28.6	42.9	47.6	12.5
Headache	35.7	21.4	19.0	43.8
Loss of smell	17.9	21.4	19.0	31.2
Loss of taste	14.3	14.3	19.0	25.0
Myalgia/fatigue	60.7	50.0	47.6	75.0
Shortness of Breath	46.4	57.1	52.4	50.0
Other symptoms	21.4	0	23.8	18.8
ICU* stay	4.0	0	4.8	0

389 *Intensive care unit

391	
392	
303	
204	
394	Finance 4. OADO Os)/ ODNA law situational also adding a damanias in standar sector of OO)//D 40
395	Figure 1. SARS-COV-2 RNA longitudinal shedding dynamics in stool samples of COVID-19
396	patients in this study. The patient IDs are snown on the y-axis. The x-axis indicates days after
397	COVID-19 diagnosis was confirmed. Patients 001–031 were enrolled as inpatients, and patients
398	035–074 were enrolled as outpatients. Three patients with unclear confirmation dates were
399	excluded from this figure. Red circles indicate positive SARS-CoV-2 detection, and blue circles
400	indicate the sample was negative for SARS-CoV-2 RNA by dPCR.
401	
402	
403	
404	
405	
405	
400	
407	Figure 2. Description of the metal cape (a)/ 2 DNA concentrations (menome conics/dm.
408	Figure 2. Boxplot of log ₁₀ -transformed SARS-CoV-2 RNA concentrations (genome copies/dry
409	gram, y-axis) in 155 fecal samples from inpatients vs. outpatients, based on status when
410	enrolled, (bottom left, x-axis) and 146 fecal samples from vaccinated vs. unvaccinated study
411	subjects (bottom right, x-axis). The horizontal lines in boxes denote the 50 th percentiles of
412	SARS-CoV-2 RNA concentrations. The top boxes represent the fraction of SARS-CoV-2 RNA
413	positive samples in each group.
414	
415	
416	Figure 3. Boxplot of log ₁₀ -transformed PMMoV concentration (genome copies/dry gram) in
417	inpatient (top) and outpatient (bottom) study subjects. Each box summarizes the range of
418	PMMoV concentrations in multiple fecal samples from an individual, and the vertical line in the
419	box represents the median PMMoV concentration. The vertical line without the box indicates
420	only one sample was tested for PMMoV for that individual.
421	
422	
423	
101	
424	
425	
426	
427	
428	

Figure 4. Boxplot of log₁₀-transformed mtDNA concentration (GC/dry gram) in inpatient (top) and outpatient (bottom) study subjects. Each box summarizes the range of mtDNA concentrations in multiple fecal samples from an individual, and the vertical line in the box represents the median mtDNA concentration. The vertical line without the box indicates only one sample was tested for mtDNA for that individual. Figure 5. Pearson correlation between log10-transformed PMMoV RNA and mtDNA concentrations (GC/dry gram) from fecal samples of inpatients (green) and outpatients (red) in this study.

460 **References**

- 461 1. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY, Chung 462 TWH, Tam AR, Yip CCY, Leung KH, Fung AY, Zhang RR, Lin Y, Cheng HM, Zhang 463 AJX, To KKW, Chan KH, Yuen KY, Leung WK. 2020. Gastrointestinal Manifestations of 464 SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: 465 Systematic Review and Meta-analysis. Gastroenterology 159:81-95. 466 2. Zhou JQ, Liu GX, Huang XL, Gan HT. 2022. The importance of fecal nucleic acid 467 detection in patients with coronavirus disease (COVID-19): A systematic review and 468 meta-analysis. J Med Virol 94:2317-2330. 469 3. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, Park RM, Han A,
- Schmidtke DT, Verma R, Jacobson KB, Parsonnet J, Bonilla HF, Singh U, Pinsky BA,
 Andrews JR, Jagannathan P, Bhatt AS. 2022. Gastrointestinal symptoms and fecal
 shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 3:371387 e9.
- 474 4. Yuan C, Wang H, Li K, Tang A, Dai Y, Wu B, Zhang H, Chen J, Liu J, Wu W, Gu S,
 475 Wang H, Xu H, Wu M, Yu M, Wang Y, Yu X, He J, Liu S, Zhang Y, Tong Z, Yan J. 2021.
 476 SARS-CoV-2 viral shedding characteristics and potential evidence for the priority for
 477 faecal specimen testing in diagnosis. PLoS One 16:e0247367.
- Jones DL, Baluja MQ, Graham DW, Corbishley A, McDonald JE, Malham SK, Hillary LS,
 Connor TR, Gaze WH, Moura IB, Wilcox MH, Farkas K. 2020. Shedding of SARS-CoV-2
 in feces and urine and its potential role in person-to-person transmission and the
 environment-based spread of COVID-19. Sci Total Environ 749:141364.
- 482 6. Nemudryi A, Nemudraia A, Wiegand T, Surya K, Buyukyoruk M, Cicha C, Vanderwood
 483 KK, Wilkinson R, Wiedenheft B. 2020. Temporal Detection and Phylogenetic
 484 Assessment of SARS-CoV-2 in Municipal Wastewater. Cell Rep Med 1:100098.
- Roka E, Khayer B, Kis Z, Kovacs LB, Schuler E, Magyar N, Malnasi T, Oravecz O, Palyi
 B, Pandics T, Vargha M. 2021. Ahead of the second wave: Early warning for COVID-19
 by wastewater surveillance in Hungary. Sci Total Environ 786:147398.
- 488
 488
 489
 489
 490
 490
 491
 491
 491
 493
 494
 494
 494
 495
 496
 496
 497
 498
 498
 499
 490
 490
 490
 490
 491
 490
 491
 490
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
- 492 9. Lu E, Ai Y, Davis A, Straathof J, Halloran K, Hull N, Winston R, Weir MH, Soller J,
 493 Bohrerova Z, Oglesbee M, Lee J. 2022. Wastewater surveillance of SARS-CoV-2 in
 494 dormitories as a part of comprehensive university campus COVID-19 monitoring.
 495 Environ Res 212:113580.
- Brooks YM, Gryskwicz B, Sidaway E, Shelley B, Coroi L, Downing M, Downing T,
 McDonnell S, Ostrye D, Hoop K, Parrish G. 2023. A case study of a communityorganized wastewater surveillance in a small community: correlating weekly reported
 COVID-19 cases with SARS-CoV-2 RNA concentrations during fall 2020 to summer
 2021 in Yarmouth, ME. J Water Health 21:329-342.
- Acosta N, Bautista MA, Hollman J, McCalder J, Beaudet AB, Man L, Waddell BJ, Chen
 J, Li C, Kuzma D, Bhatnagar S, Leal J, Meddings J, Hu J, Cabaj JL, Ruecker NJ,
 Naugler C, Pillai DR, Achari G, Ryan MC, Conly JM, Frankowski K, Hubert CR, Parkins
 MD. 2021. A multicenter study investigating SARS-CoV-2 in tertiary-care hospital
 wastewater. viral burden correlates with increasing hospitalized cases as well as
 hospital-associated transmissions and outbreaks. Water Res 201:117369.
- Ai Y, Davis A, Jones D, Lemeshow S, Tu H, He F, Ru P, Pan X, Bohrerova Z, Lee J.
 2021. Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend
 tracker and variants in Ohio, United States. Sci Total Environ 801:149757.

- 510 13. McMahan CS, Lewis D, Deaver JA, Dean D, Rennert L, Kalbaugh CA, Shi L, Kriebel D,
 511 Graves D, Popat SC, Karanfil T, Freedman DL. 2022. Predicting COVID-19 Infected
 512 Individuals in a Defined Population from Wastewater RNA Data. ACS ES T Water
 513 2:2225-2232.
- 514 14. Joseph-Duran B, Serra-Compte A, Sarrias M, Gonzalez S, Lopez D, Prats C, Catala M,
 515 Alvarez-Lacalle E, Alonso S, Arnaldos M. 2022. Assessing wastewater-based
 516 epidemiology for the prediction of SARS-CoV-2 incidence in Catalonia. Sci Rep
 517 12:15073.
- 518 15. McMahan CS, Self S, Rennert L, Kalbaugh C, Kriebel D, Graves D, Colby C, Deaver JA,
 519 Popat SC, Karanfil T, Freedman DL. 2021. COVID-19 wastewater epidemiology: a
 520 model to estimate infected populations. Lancet Planet Health 5:e874-e881.
- 521 16. Proverbio D, Kemp F, Magni S, Ogorzaly L, Cauchie HM, Goncalves J, Skupin A, Aalto
 522 A. 2022. Model-based assessment of COVID-19 epidemic dynamics by wastewater
 523 analysis. Sci Total Environ 827:154235.
- 524 17. Zhang T, Breitbart M, Lee WH, Run JQ, Wei CL, Soh SW, Hibberd ML, Liu ET, Rohwer
 525 F, Ruan Y. 2006. RNA viral community in human feces: prevalence of plant pathogenic
 526 viruses. PLoS Biol 4:e3.
- Maal-Bared R, Qiu Y, Li Q, Gao T, Hrudey SE, Bhavanam S, Ruecker NJ, Ellehoj E, Lee
 BE, Pang X. 2023. Does normalization of SARS-CoV-2 concentrations by Pepper Mild
 Mottle Virus improve correlations and lead time between wastewater surveillance and
 clinical data in Alberta (Canada): comparing twelve SARS-CoV-2 normalization
 approaches. Sci Total Environ 856:158964.
- Ahmed W, Bivins A, Payyappat S, Cassidy M, Harrison N, Besley C. 2022. Distribution
 of human fecal marker genes and their association with pathogenic viruses in untreated
 wastewater determined using quantitative PCR. Water Res 226:119093.
- 535 20. Hajj-Mohamad M, Hachad M, Deschamps G, Sauve S, Villemur R, Blais MA, Prevost M,
 536 Dorner S. 2019. Fecal contamination of storm sewers: Evaluating wastewater
 537 micropollutants, human-specific Bacteroides 16S rRNA, and mitochondrial DNA genetic
 538 markers as alternative indicators of sewer cross connections. Sci Total Environ 659:548539 560.
- S40 21. Ragot R, Villemur R. 2022. Influence of temperature and water quality on the
 S41 persistence of human mitochondrial DNA, human Hf183 Bacteroidales, fecal coliforms
 S42 and enterococci in surface water in human fecal source tracking context. Sci Total
 S43 Environ 838:156025.
- 54422.Zhu K, Suttner B, Pickering A, Konstantinidis KT, Brown J. 2020. A novel droplet digital545PCR human mtDNA assay for fecal source tracking. Water Res 183:116085.
- 546 23. Tanvir Pasha ABM, Hinojosa J, Phan D, Lopez A, Kapoor V. 2020. Detection of human
 547 fecal pollution in environmental waters using human mitochondrial DNA and correlation
 548 with general and human-associated fecal genetic markers. J Water Health 18:8-18.
- 549 24. Bajpai J, Kant S, Verma A, Patwa AK, Atam V, Chaudhary SC, Pandey A. 2022. The
 550 Severity of COVID 19 Pneumonia in Vaccinated vs. Non-vaccinated Patients in the
 551 Second Wave: An Experience From a Tertiary Care Center in India. Cureus 14:e25378.
- S52 25. Nakakubo S, Kishida N, Okuda K, Kamada K, Iwama M, Suzuki M, Yokota I, Ito YM,
 S53 Nasuhara Y, Boucher RC, Konno S. 2023. Associations of COVID-19 symptoms with
 omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a
 registry-based observational study. Lancet Infect Dis 23:1244-1256.
- 55626.Tian Ŵ, Ren X, Han M, Zhang Y, Gao X, Chen Z, Zhang W. 2022. Epidemiological and557clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic558review. Int J Immunopathol Pharmacol 36:3946320221141802.
- Arts PJ, Kelly JD, Midgley CM, Anglin K, Lu S, Abedi GR, Andino R, Bakker KM,
 Banman B, Boehm AB, Briggs-Hagen M, Brouwer AF, Davidson MC, Eisenberg MC,

561 Garcia-Knight M. Knight S. Peluso MJ. Pineda-Ramirez J. Diaz Sanchez R. Savdah S. 562 Tassetto M, Martin JN, Wigginton KR. 2023. Longitudinal and quantitative fecal shedding 563 dynamics of SARS-CoV-2, pepper mild mottle virus, and crAssphage. mSphere 564 8:e0013223. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, Zhao J, Huang J, Zhao J. 2020. Infectious 565 28. 566 SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis 26:1920-567 1922. 568 29. Jeong HW, Kim SM, Kim HS, Kim YI, Kim JH, Cho JY, Kim SH, Kang H, Kim SG, Park 569 SJ, Kim EH, Choi YK. 2020. Viable SARS-CoV-2 in various specimens from COVID-19 570 patients. Clin Microbiol Infect 26:1520-1524. 571 Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020. Detection of SARS-CoV-2 in 30. 572 Different Types of Clinical Specimens. JAMA 323:1843-1844. 573 31. Zhang YN, Zhang QY, Li XD, Xiong J, Xiao SQ, Wang Z, Zhang ZR, Deng CL, Yang XL, 574 Wei HP, Yuan ZM, Ye HQ, Zhang B. 2020. Gemcitabine, lycorine and oxysophoridine 575 inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg Microbes Infect 9:1170-576 1173. 577 32. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, 578 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, 579 Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of 580 hospitalized patients with COVID-2019. Nature 581:465-469. 581 33. Albert S, Ruiz A, Peman J, Salavert M, Domingo-Calap P. 2021. Lack of evidence for 582 infectious SARS-CoV-2 in feces and sewage. Eur J Clin Microbiol Infect Dis 40:2665-583 2667. 584 Britton GJ, Chen-Liaw A, Cossarini F, Livanos AE, Spindler MP, Plitt T, Eggers J, Mogno 34. 585 I, Gonzalez-Reiche AS, Siu S, Tankelevich M, Grinspan LT, Dixon RE, Jha D, van de 586 Guchte A, Khan Z, Martinez-Delgado G, Amanat F, Hoagland DA, tenOever BR, 587 Dubinsky MC, Merad M, van Bakel H, Krammer F, Bongers G, Mehandru S, Faith JJ. 588 2021. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-589 specific IgA in patients with acute COVID-19. Sci Rep 11:13308. 590 35. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens 591 TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. 2020. SARS-592 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 593 Proven Protease Inhibitor. Cell 181:271-280 e8. 594 Maffia-Bizzozero S, Cevallos C, Lenicov FR, Freiberger RN, Lopez CAM, Guano 36. 595 Toaquiza A, Sviercz F, Jarmoluk P, Bustos C, D'Addario AC, Quarleri J, Delpino MV. 596 2023. Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues. Front 597 Microbiol 14:1192832. 598 37. Holm RH, Nagarkar M, Yeager RA, Talley D, Chaney AC, Rai JP, Mukherjee A, Rai SN, 599 Bhatnagar A, Smith T. 2022. Surveillance of RNase P, PMMoV, and CrAssphage in 600 wastewater as indicators of human fecal concentration across urban sewer 601 neighborhoods, Kentucky. FEMS Microbes 3:1-12. 602 38. Hamza H, Rizk NM, Gad MA, Hamza IA. 2019. Pepper mild mottle virus in wastewater in 603 Egypt: a potential indicator of wastewater pollution and the efficiency of the treatment 604 process. Arch Virol 164:2707-2713. 605 39. Chettleburgh C, Ma SX, Swinwood-Sky M, McDougall H, Kireina D, Taggar G, McBean 606 E, Parreira V, Goodridge L, Habash M. 2023. Evaluation of four human-associated fecal 607 biomarkers in wastewater in Southern Ontario. Sci Total Environ 904:166542. 608 40. He Z, Dong L, Zhu P, Zhang Z, Xu T, Zhang D, Pan X. 2022. Nano-scale analysis of 609 uranium release behavior from river sediment in the Ili basin. Water Res 227:119321. 610 41. Greenwald HD, Kennedy LC, Hinkle A, Whitney ON, Fan VB, Crits-Christoph A, Harris-611 Lovett S, Flamholz AI, Al-Shayeb B, Liao LD, Beyers M, Brown D, Chakrabarti AR, Dow

- J, Frost D, Koekemoer M, Lynch C, Sarkar P, White E, Kantor R, Nelson KL. 2021.
 Tools for interpretation of wastewater SARS-CoV-2 temporal and spatial trends
 demonstrated with data collected in the San Francisco Bay Area. Water Res X
 12:100111.
- 616 42. Crank K, Li X, North D, Ferraro GB, Iaconelli M, Mancini P, La Rosa G, Bibby K. 2020.
 617 CrAssphage abundance and correlation with molecular viral markers in Italian
 618 wastewater. Water Res 184:116161.
- Malla B, Makise K, Nakaya K, Mochizuki T, Yamada T, Haramoto E. 2019. Evaluation of Human- and Animal-Specific Viral Markers and Application of CrAssphage, Pepper Mild Mottle Virus, and Tobacco Mosaic Virus as Potential Fecal Pollution Markers to River
 Water in Japan. Food Environ Virol 11:446-452.
- 623 44. Rosario K, Symonds EM, Sinigalliano C, Stewart J, Breitbart M. 2009. Pepper mild 624 mottle virus as an indicator of fecal pollution. Appl Environ Microbiol 75:7261-7.
- 45. Zhu KJ, Suttner B, Knee J, Capone D, Moe CL, Stauber CE, Konstantinidis KT, Wallach
 626 TE, Pickering AJ, Brown J. 2022. Elevated Fecal Mitochondrial DNA from Symptomatic
 627 Norovirus Infections Suggests Potential Health Relevance of Human Mitochondrial DNA
 628 in Fecal Source Tracking. Environ Sci Technol Lett 9:543-550.
- He X, Liu P, Zheng G, Chen H, Shi W, Cui Y, Ren H, Zhang XX. 2016. Evaluation of five
 microbial and four mitochondrial DNA markers for tracking human and pig fecal pollution
 in freshwater. Sci Rep 6:35311.









